Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma
- PDF / 817,670 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 213 Views
RESEARCH ARTICLE
Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma S. Cabrera1,2 · V. Bebia1 · U. Acosta3 · S. Franco‑Camps1 · L. Mañalich3 · A. García‑Jiménez2,4 · A. Gil‑Moreno2,3 Received: 7 June 2020 / Accepted: 10 October 2020 © Federación de Sociedades Españolas de Oncología (FESEO) 2020
Abstract Purpose To review the diagnostic and therapeutic procedures of patients diagnosed with Endometrial Stromal Sarcoma (ESS) and Undifferentiated Uterine Sarcoma (USS) at our institution and investigate their clinical outcomes and factors affecting prognosis. Methods We retrospectively collected demographic data, preoperative diagnostic methods and therapeutic management of patients treated for ESS and UUS between January 1995 and December 2019 at Vall d’Hebron Barcelona Hospital Campus, Spain. Overall survival and disease-free survival were calculated. Cox proportional-hazards regression models were calculated. Results Sixty-three patients were included in the study, of which 51(81%) had a diagnosis of ESS and 12(19%) of UUS. Twenty patients (31.7%) were diagnosed after a previous non-oncologic surgery, and 12 of them (60%) suffered from tumor disruption. Cytoreductive procedures were needed in 29 patients (46%), and optimal cytoreduction was achieved in 80.9% of the patients. The median follow-up was 7.6 years (IQR = 0.99–14.31). Five-year overall survival was 57.6% (44.2–68.8) and was significantly better for low-grade ESS (LG-ESS) patients (p
Data Loading...
